Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Stopped early · Phase 3

Conditions studied: Multiple Sclerosis, Relapsing-Remitting

In brief

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks. The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.

Key facts

Study ID: NCT03085810
Run by: Hoffmann-La Roche
People needed: 1225
Starts: 2017-03-24
Expected to finish: 2023-04-27
Last updated by the study team: 2025-01-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have a definite diagnosis of RRMS, as per the revised McDonald 2010 criteria
Have a length of disease duration, from first documented clinical attack consistent with MS disease of less than or equal to (</=) 3 years
Within the last 12 months one or more clinically reported relapse(s) or one or more signs of MRI activity
EDSS of 0.0 to 3.5 inclusive, at screening
An agreement to use an acceptable birth control method for women of childbearing potential, during the treatment period and for at least 6 months or longer after the last dose of study drug

You may not qualify if…

Secondary progressive multiple sclerosis or history of primary progressive or progressive relapsing MS
Inability to complete an MRI
Known presence of other neurological disorders
Exclusions Related to General Health:
Pregnancy or lactation
Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug
Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
History or currently active primary or secondary immunodeficiency
Lack of peripheral venous access
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
Significant or uncontrolled somatic disease or any other significant disease that may preclude participant from participating in the study
Congestive heart failure (New York Heart Association III or IV functional severity)
Known active bacterial, viral, fungal, mycobacterial infection or other infection, (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to screening or oral antibiotics 2 weeks prior to screening
History of malignancy, major opportunistic infections, alcohol or drug abuse, recurrent or chronic infection, and/or coagulation disorders
Exclusions Related to Medications:
Received any prior approved disease modifying treatment (DMT) with a label for MS, for example, interferons, glatiramer acetate, natalizumab, alemtuzumab, daclizumab, fingolimod, teiflunomide and dimethylfumarate
Receipt of a live vaccine or attenuated live vaccine within 6 weeks prior to the baseline visit
Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
Any previous treatment with immunosuppressants/ immunomodulators/ antineoplastic therapies (cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cladribine, mitoxantrone, laquinimod, total body irradiation, or bone marrow transplantation)
Treatment with investigational DMT
Treatment with fampridine/dalfamipridine unless on stable dose for >/=30 days prior to screening
Exclusion related to Shorter Infusion Substudy:
Any previous serious IRRs experienced with ocrelizumab treatment

Where it is running

Palo Alto Medical Foundation Research Center — Sunnyvale, California, United States
University of Colorado Denver — Aurora, Colorado, United States
Advanced Neurology of Colorado, LLC — Fort Collins, Colorado, United States
KI Health Partners, LLC; New England Institute for Clinical Research — Stamford, Connecticut, United States
Georgetown University Medical Center — Washington D.C., District of Columbia, United States
University of South Florida - Bradenton — Tampa, Florida, United States
Shepherd Center Inc. — Atlanta, Georgia, United States
College Park Family Care Ctr — Overland Park, Kansas, United States
The NeuroMedical Center — Baton Rouge, Louisiana, United States
Maine Medical Center — Scarborough, Maine, United States
University of Maryland Medical Center; Department of Neurology — Baltimore, Maryland, United States
Neurology Center of New England — Foxborough, Massachusetts, United States
Dragonfly Research, LLC — Wellesley, Massachusetts, United States
Minneapolis Clinic of Neurology — Golden Valley, Minnesota, United States
Cleveland Clinic Lou Ruvo; Center for Brain Research — Las Vegas, Nevada, United States
Columbia University Medical Center — New York, New York, United States
Island Neurological Associates, P.C. — Plainview, New York, United States
Neurology Associates PA — Hickory, North Carolina, United States
Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40 — Cleveland, Ohio, United States
Neurology Specialists, Inc — Dayton, Ohio, United States
Vanderbilt University Medical Center — Nashville, Tennessee, United States
Kane Hall Barry Neurology — Bedford, Texas, United States
MultiCare Health System Institute for Research and Innovation — Tacoma, Washington, United States
University of California Irvine — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.